2021-06-06-世界卫生组织-GLASS_guide for_hospital_AMC surveillance_– _Use_of_surveillance_data_for_policy_making_15页_1mb

GLASS Report Analysis Summary

1. Use Of Surveillance Data For Policy Making

• Surveillance data from GLASS informs actions at global, national, and health care facility levels. Global applications include informing essential medicines lists, monitoring AMR trends, and assessing intervention effectiveness. National-level uses involve guiding national medicines policies and treatment guidelines. At the health care facility level, data supports early detection of emerging AMR and infection prevention strategies.

2. Optimizing Data Use Considerations

• Key factors include identifying the specific data needed for interventions at different levels, evaluating data quality and limitations, and engaging stakeholders with effective communication methods.

3. Points For Policy Makers

• Policymakers should prioritize defining interventions to align with data needs and be aware of data limitations. Note that surveillance data from routinely collected samples may be biased in areas with limited lab access; targeted surveys are recommended to address biases.

4. Assessing AMR Burden

• Attributable mortality is estimated using Disability-Adjusted Life-Years (DALYs), focusing on bloodstream infections like MRSA and drug-resistant E. coli. GLASS methodology employs a prospective cohort study to compare case-fatality rates, and data are crucial for SDG Target 3.d, emphasizing the need for accurate global estimates to prioritize public health spending and international efforts.

5. GLASS Protocol Usefulness

• Feedback indicates that 100% of countries find the GLASS protocol useful and capable of implementation for estimating AMR burden, though it requires additional effort compared to routine surveillance.

6. Considerations For AMR Burden Estimation

• Accurate AMR burden estimates are vital for national and global prioritization of health spending and advancing international AMR efforts. However, measuring attributable mortality involves specific surveys, which can be resource-intensive and prone to bias if data limitations exist.

7. Monitoring National Surveillance Systems

• GLASS monitors national AMR/AMU surveillance through coordinated efforts, including system structure and quality control. The Tripartite Antimicrobial Resistance Country Self-Assessment Survey (TrACSS) shows that lab access is often limited, with only 35.1% of responses indicating adequate infrastructure.

8. Progressive AMR Surveillance Pathway

• This pathway includes defined indicators and targets for stepwise development, encompassing structure, process, and outcome measures to evaluate surveillance system impact and guide national improvements, aligning with the Tripartite monitoring framework.